| Bid | 17.8 |
| Market Cap | 1.21B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.11 |
| PE Ratio (ttm) | -23.59 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 28.5 |
| Volume | 240,234 |
| Avg. Volume (20D) | 388,888 |
| Open | 27.48 |
| Previous Close | 26.97 |
| Day's Range | 25.42 - 27.74 |
| 52-Week Range | 14.50 - 28.88 |
| Beta | undefined |
About BLFS
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are form...
Analyst Forecast
According to 7 analyst ratings, the average rating for BLFS stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 18.37% from the latest price.
Next Earnings Release
Analysts project revenue of $22.77M, reflecting a -30.44% YoY shrinking and earnings per share of -0.03, making a -85.71% decrease YoY.
1 week ago · https://thefly.com
BioLife Solutions price target raised to $31 from $28 at NorthlandNorthland raised the firm's price target on BioLife Solutions to $31 from $28 and keeps an Outperform rating on the shares. With the divestiture of its freezer businesses and the recent sale of SciSaf...
